Separate a short experiment from a lasting clinical result
The displayed methylene-blue study enrolled twenty-six people in a randomized imaging experiment. It measured brain imaging and task performance before and after administration. That observation period is part of the finding.
The growth-hormone-releasing-factor paper administered several related peptide sequences intravenously to small groups of volunteers. It measured short-term growth-hormone responses. This is a different research question from a long-term clinical outcome for the current sermorelin product.
Sources: PMID 27351678 · PMID 6240568
Distinguish the administered material from a related pathway
The NAD+ catalog includes injectable and nasal products. A study of a precursor such as nicotinamide riboside uses a different administered material from NAD+ itself. Research describing NAD biology can be relevant to the pathway while leaving the route-specific product question open.
Glutathione publications can measure the molecule in normal biology, test it in cells or administer a preparation. These categories need to stay separate before the evidence is connected to the 200 mg/mL injectable listing.
The study population determines the question
A metformin study in diabetes prevention starts with a different population and endpoint from a study in another setting. Vitamin B12 replacement research also depends on baseline status and the preparation tested.
The individual ingredient pages expose the full search query and a focused bibliography where available. Their publication counts describe those searches, including research outside longevity, without combining unrelated results into a single effectiveness score.
The formulation network
Each row connects a current product to the ingredient research behind its listed formulation.
Read the source studies
Research synthesis by HealthRX.com, October 5, 2026. The cited sources and linked ingredient pages describe the scope of this comparison.